DEPDC1 and cancer: Another cancer vaccine comprising two HLA-A*24:02-restricted peptides from DEP domain containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1) afforded prolonged survival in CTL-induced patients with advanced urothelial carcinoma of the bladder [11].